Materialise NV (MTLS) Q4 2025 Earnings Call Transcript

Why It Matters

The shift toward a high‑margin medical franchise and recurring software revenue cushions Materialise against downturns in its traditional manufacturing business, positioning it for sustainable growth in additive‑manufacturing‑enabled healthcare and defense markets.

Key Takeaways

• Medical revenue hits €33.3M, 10% YoY growth.
• Software and Manufacturing revenues down 7% and 17%.
• Operating cash flow rises to €10.4M, net cash €67.7M.
• Software recurring revenue reaches 83%, up from 74%.
• Adjusted EBIT margin falls to 4.4%, below prior year.

Pulse Analysis

Materialise’s third‑quarter results underscore a decisive pivot toward its medical franchise. The segment posted an all‑time high of €33.3 million, driven by double‑digit growth in both device sales and software licences. Recent launches such as the FEops Heart Guide and the AI‑enhanced Mimics Enlight CMF planner have delivered clinical evidence of up to 91 % procedural time savings, reinforcing the company’s position in cardiac and trauma care. This momentum not only lifts overall revenue mix—medical now accounts for half of total sales—but also validates Materialise’s strategy of integrating additive‑manufacturing expertise with cloud‑based planning tools.

Despite the medical surge, Materialise’s Software and Manufacturing divisions remain under pressure, with revenues falling 7 % and 17 % respectively due to lingering macroeconomic headwinds and a weaker U.S. dollar. The company’s shift toward subscription models is evident: recurring software revenue climbed to 83 % of the segment, up from 74 % a year earlier, improving cash predictability. Cost discipline has kept operating expenses flat, while operating cash flow rose to €10.4 million and net cash reached €67.7 million, providing a solid liquidity cushion to weather short‑term market volatility.

Looking ahead, Materialise maintains its FY2025 guidance of €265‑€280 million revenue and adjusted EBIT of €6‑€10 million, betting on continued expansion in high‑growth niches such as cardiac, trauma and defense. Investments in ACTech’s giga‑casting capabilities and defense‑sector engagements aim to capture demand for large, complex metal parts and mission‑critical components. The ongoing R&D spend of over €11 million, primarily in medical, signals a commitment to innovation pipelines that could sustain the medical franchise’s premium pricing power. If macro conditions stabilize, the blend of recurring software revenue and additive‑manufacturing expertise positions Materialise for incremental earnings upside.